Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL). A Phase II FILO Trial

NCT07624799 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT07624799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07624799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL). A Phase II FILO Trial
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2033
Enrollment
82 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cll (chronic lymphocytic leukemia)